Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

The BOOST trial - led by researchers at the University of Plymouth and experts across the UK - will assess whether the Β-hydroxy β-methylbutyrate (HMB) supplement can benefit some of the 60,000 people ...

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...

When receiving suitable treatment for the underlying liver condition, it may be possible to reverse some damage. For example, there are cases of reversing cirrhosis in those living with hepatitis ...

SNUBBING Dry January and continuing to drink like it’s Christmas may seem like a great way to get through the dreary first ...

Akero Therapeutics shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.

For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

A Cleveland Clinic study reveals that bariatric surgery significantly reduces the risk of serious liver complications in ...

A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future risk of developing serious liver complications ...